Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Domenico Mangiameli
Institution:
University of Verona
Observed institution:
University of Verona
ORCID:
0000-0003-2577-1277
Observed ORCID:
0000-0003-2577-1277
OpenAlex ID:
A5028453073
Targeting KRAS: The Elephant in the Room of Epithelial Cancers
2021
·
Valeria Merz
, Marina Gaule
, et al.
·
Frontiers in Oncology
·
81
PDF
The Multifaceted Role of TGF-β in Gastrointestinal Tumors
2021
·
Fabio Sabbadini
, Monica Bertolini
, et al.
·
Cancers
·
47
PDF
Autotaxin Secretion Is a Stromal Mechanism of Adaptive Resistance to TGFβ Inhibition in Pancreatic Ductal Adenocarcinoma
2023
·
Silvia Pietrobono
, Fabio Sabbadini
, et al.
·
Cancer Research
·
37
Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer
2020
·
Valeria Merz
, Camilla Zecchetto
, et al.
·
Clinical Cancer Research
·
30
CCL3 predicts exceptional response to TGFβ inhibition in basal-like pancreatic cancer enriched in LIF-producing macrophages
2024
·
Silvia Pietrobono
, Monica Bertolini
, et al.
·
npj Precision Oncology
·
16
p38 MAPK-dependent phosphorylation of transcription factor SOX2 promotes an adaptive response to BRAF inhibitors in melanoma cells
2022
·
Silvia Pietrobono
, Raffaella De Paolo
, et al.
·
Journal of Biological Chemistry
·
14
YAP Activation Is Associated with a Worse Prognosis of Poorly Cohesive Gastric Cancer
2023
·
Maria Bencivenga
, Lorena Torroni
, et al.
·
Journal of Personalized Medicine
·
9
PDF
Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer
2022
·
Valeria Merz
, Domenico Mangiameli
, et al.
·
Frontiers in Surgery
·
8
PDF
Injectable Thermogelling Nanostructured Ink as Simultaneous Optical and Magnetic Resonance Imaging Contrast Agent for Image-Guided Surgery
2024
·
Chiara Cressoni
, Sarah Malandra
, et al.
·
Biomacromolecules
·
2
EGFR ligand Angiogenin predicts response to ALK5 inhibition in pancreatic cancer via a TNF-α paracrine axis in tumor-associated macrophages
2026
·
Silvia Pietrobono
, Veronica De Vita
, et al.
·
Oncogene
·
1
PDF
Targeting FGFR Pathway Is Not an Effective Therapeutic Strategy in Patients with Unselected Metastatic Esophagogastric Cancer Resistant to Trastuzumab
2023
·
Camilla Zecchetto
, Alberto Quinzii
, et al.
·
Journal of Personalized Medicine
·
1
PDF
Author Correction: CCL3 predicts exceptional response to TGFβ inhibition in basal-like pancreatic cancer enriched in LIF-producing macrophages
2026
·
Silvia Pietrobono
, Monica Bertolini
, et al.
·
npj Precision Oncology
PDF
Abstract 2495: CCL3 predicts an exceptional response to TGFβ inhibition in pancreatic ductal adenocarcinoma by sustaining a basal-like ecotype enriched in LIF-producing macrophages
2024
·
Silvia Pietrobono
, Monica Bertolini
, et al.
·
Cancer Research
Supplementary Data from Autotaxin Secretion Is a Stromal Mechanism of Adaptive Resistance to TGFβ Inhibition in Pancreatic Ductal Adenocarcinoma
2024
·
Silvia Pietrobono
, Fabio Sabbadini
, et al.
Data from Autotaxin Secretion Is a Stromal Mechanism of Adaptive Resistance to TGFβ Inhibition in Pancreatic Ductal Adenocarcinoma
2024
·
Silvia Pietrobono
, Fabio Sabbadini
, et al.
Data from Autotaxin Secretion Is a Stromal Mechanism of Adaptive Resistance to TGFβ Inhibition in Pancreatic Ductal Adenocarcinoma
2024
·
Silvia Pietrobono
, Fabio Sabbadini
, et al.
Supplementary TABLE 1 from Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer
2023
·
Valeria Merz
, Camilla Zecchetto
, et al.
Figure S3. from Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer
2023
·
Valeria Merz
, Camilla Zecchetto
, et al.
Figure S4. from Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer
2023
·
Valeria Merz
, Camilla Zecchetto
, et al.
PDF
Figure S5. from Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer
2023
·
Valeria Merz
, Camilla Zecchetto
, et al.
Figure S2. from Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer
2023
·
Valeria Merz
, Camilla Zecchetto
, et al.
PDF
Figure S12. from Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer
2023
·
Valeria Merz
, Camilla Zecchetto
, et al.
PDF
Figure S6. from Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer
2023
·
Valeria Merz
, Camilla Zecchetto
, et al.
Figure S1. from Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer
2023
·
Valeria Merz
, Camilla Zecchetto
, et al.
PDF
Figure S7. from Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer
2023
·
Valeria Merz
, Camilla Zecchetto
, et al.
Show more works
View as search
Works count:
49
Citation count:
246
H-index:
8
I10-index:
6
Year
Topic
Type